LMWH is the Dominant Heparin Product Market in Europe and is Expected to Reach USD 3.14 Billion in 2022 - PowerPoint PPT Presentation

slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
LMWH is the Dominant Heparin Product Market in Europe and is Expected to Reach USD 3.14 Billion in 2022 PowerPoint Presentation
Download Presentation
LMWH is the Dominant Heparin Product Market in Europe and is Expected to Reach USD 3.14 Billion in 2022

play fullscreen
1 / 11
LMWH is the Dominant Heparin Product Market in Europe and is Expected to Reach USD 3.14 Billion in 2022
275 Views
Download Presentation
Alinajohn
Download Presentation

LMWH is the Dominant Heparin Product Market in Europe and is Expected to Reach USD 3.14 Billion in 2022

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Transparency Market Research Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2022 Published Date 2015-06-12 68 Page Report Request Sample Buy Now Press Release Germany Expected to be the Fastest Growing Heparin Market in Europe Expanding at a CAGR of 6.0% by 2022 Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com

  2. Heparin Market REPORT DESCRIPTION According to a new market report published by Transparency Market Research Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022” the Europe heparin market was valued at USD 2,004.5 million in 2013 and is estimated to reach USD 3,148.0 million by 2022 growing with a CAGR of 5.2% from 2014 to 2022. Browse the full Heparin Market (Unfractionated Heparin, Low Molecular Weight Heparin & Ultra Low Molecular Weight Heparin) - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 report at http://www.transparencymarketresearch.com/europe-heparin-market.html The heparin market in Europe has been categorized into major national markets namely, the United Kingdom, Germany, Spain, Italy, France, and Rest of Europe. The European market is among the major contributors to the global heparin market owing to its developed economy and high prevalence of coagulation disorders. In the current scenario, according to the 2015 Ageing Report by the European Commission, the percentage of population aged above 65 years is expected to increase from 21% in 2013 to 32% in 2060. As aging is proportional to increasing incidences of VTE diseases such as deep vein thrombosis (DVT) and pulmonary embolism (PE) demand for heparin is expected to increase in coming years. Germany accounts for the largest market share in the overall Europe heparin market accounting for around 274.8 million in 2013. Key attributes to the market growth in Germany encompasses burgeoning population of venous thromboembolism (VTE) patients owing to which the consumption of heparin has grown at a rapid pace over the past few years. Moreover, ban of Chinese APIs due to adulterated issue leading to over 100 deaths in the U.S., has drastically attracted new players in heparin processing and manufacturing business. For instance in 2013, German meat company Tönnies group acquired heparin API manufacturer Pharma Action which proposed to manufacture 30 metric tons of API in forthcoming years. For instance, Germany-based meat company Tönnies Group entered the heparin processing business by acquiring heparin API maker Pharma Action. Such developments are expected to augment heparin market in Germany. Followed by Germany, France has major contribution to the heparin market in the Europe. Each year 370,000 deaths in France occur due to VTE. Moreover, Heparin consumption during and after surgical procedures such as knee replacement, hip surgeries, appendectomy and breast surgeries are relatively high compared to Italy, Spain and United Kingdom. It is estimated that every fourth person in France by 2020 would be aged above 60 years. Rapidly aging population and growing life expectancy would increase the risk of thrombosis among the geriatric population. According to the Thrombosis Research Institute, around 25,000 deaths occur annually in England due to hospital-contracted VTE. Based on 2 Transparency Market Research

  3. Heparin Market the recommendations from the chief medical officer (CMO), the Department of Health in the U.K. published an operating framework for the NHS in England. This framework requires risk assessment to be done for thrombosis in a minimum of 90% of patients admitted to hospitals. All these factors are likely to support the growth in demand for heparin for prophylaxis and treatment of thrombosis during the forecast period. Browse the full Press Release Report : http://www.transparencymarketresearch.com/pressrelease/geography-heparin- market.htm Spain, Italy and Rest of the Europe markets although have low revenue contribution in European heparin market is expected to grow in forthcoming years. Spain's National Institute of Statistics (INE) predicts that the Spanish population would shrink by 5.6 million before 2064. Additionally, about 40% of the population would be aged over 65 years, which is an increase from 18.2% in 2013. The United Nations (UN) projects that Spain would be the world’s oldest country by 2050. This is a major factor attributed to an increased risk of thrombosis, which would further propel demand for heparin in the region. Such factors along with increasing investment in elderly care would propel the demand for heparin in Italy. As of 2014, there is only one drug licensed (Rivaroxaban; Xarelto) for the treatment of VTE in Italy. Advent of biosimilars would augment the growth of heparin market in Italy during the forecast period. Some of the key players profiled in this report include Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Leo Pharma A/S, Pfizer, Inc., Sanofi S.A., and Syntex S.A. are profiled in this report.   The Europe Heparin Market is segmented into the following categories: Europe Heparin Market, by Product Unfractionated Heparin Low Molecular Weight Heparin (LMWHs) Ultra-low Molecular Weight Heparin (ULMWHs) Europe Heparin Market, by Country United Kingdom Unfractionated Heparin Low Molecular Weight Heparin (LMWHs) Ultra-low Molecular Weight Heparin (ULMWHs) 3 Transparency Market Research

  4. Heparin Market Germany Unfractionated Heparin Low Molecular Weight Heparin (LMWHs) Ultra-low Molecular Weight Heparin (ULMWHs) France Unfractionated Heparin Low Molecular Weight Heparin (LMWHs) Ultra-low Molecular Weight Heparin (ULMWHs) Spain Unfractionated Heparin Low Molecular Weight Heparin (LMWHs) Ultra-low Molecular Weight Heparin (ULMWHs) Italy Unfractionated Heparin Low Molecular Weight Heparin (LMWHs) Ultra-low Molecular Weight Heparin (ULMWHs) Rest of the Europe Unfractionated Heparin Low Molecular Weight Heparin (LMWHs) Ultra-low Molecular Weight Heparin (ULMWHs) Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=4815 Table of Contents Chapter 1 Introduction 4 Transparency Market Research

  5. Heparin Market 1.1 Report Description 1.2 Research Methodology 1.2.1 Secondary Research 1.2.1 Primary Research 1.3 Assumptions and Stipulations 1.4 Market Segmentation Chapter 2 Executive Summary Chapter 3 Market Overview 3.1 Introduction 3.2 Market Drivers 3.2.1 Rising incidence of coagulation and renal disorders in Europe to propel demand for heparin products 3.2.2 Ban on imports from China to boost production in European 3.2.3 Inclination of slaughterhouse owners to enter crude heparin processing business expected to overcome demand supply gap in Europe 3.3 Market Restraints 3.3.1 Presence of alternatives such as synthetic heparin and other anticoagulants impeding sales of biological-based heparin products 3.3.2 Enhanced quality control measures and environmental factors elevating the cost of heparin production 3.4 Market Opportunities 3.4.1 Biosimilars as an alternative to biological based products 3.4.2 Research activities on marine-based heparin products 3.5 Value Chain Analysis: Europe Heparin Market 3.6 Market Attractiveness Analysis: Europe Heparin Market, by Country 5 Transparency Market Research

  6. Heparin Market 3.7 Market Share Analysis: Europe Heparin Market, by Key Players, 2013 3.8 Average Pricing Chapter 4 Europe Heparin Market, by Product 4.1 Introduction 4.1.1 Europe Heparin Market Revenue, by Product, 2012 – 2022 (USD Million) 4.2 Unfractionated Heparin 4.2.1 Europe Unfractionated Heparin Market Revenue, 2012 – 2022 (USD Million) 4.3 Low Molecular Weight Heparin 4.3.1 Europe Low Molecular Weight Heparin Market Revenue, 2012 – 2022 (USD Million) 4.4 Ultra-low Molecular Weight Heparin 4.4.1 Europe Ultra-low Molecular Weight Heparin Market Revenue, 2012 – 2022 (USD Million) Chapter 5 Europe Heparin Market, by Country 5.1 Overview 5.1.1 Europe Heparin Market Revenue, by Country, 2012 – 2022 (USD Million) 5.1.2 United Kingdom 5.1.2.1 United Kingdom Heparin Market Revenue, by Product, 2012 – 2022 (USD Million) 5.1.3 Germany 5.1.3.1 Germany Heparin Market Revenue, by Product, 2012 – 2022 (USD Million) 5.1.4 France 5.1.4.1 France Heparin Market Revenue, by Product, 2012 – 2022 (USD Million) 5.1.5 Spain 5.1.5.1 Spain Heparin Market Revenue, by Product, 2012 – 2022 (USD Million) 6 Transparency Market Research

  7. Heparin Market 5.1.6 Italy 5.1.6.1 Italy Heparin Market Revenue, by Product, 2012 – 2022 (USD Million) 5.1.7 Rest of Europe (RoE) 5.1.7.1 Rest of Europe Heparin Market Revenue, by Product, 2012 – 2022 (USD Million) Chapter 6 Recommendations 6.1 Perform Quality Measures 6.2 Commercializing Biosimilars at a Lower Cost to Increase its Preference Over the Branded Products Chapter 7 Company Profiles 7.1 Dr. Reddy’s Laboratories Ltd. 7.1.1 Company Overview 7.1.2 Financial Overview 7.1.3 Product Portfolio 7.1.4 Business Strategies 7.1.5 Recent Developments 7.2 Fresenius Kabi AG 7.2.1 Company Overview 7.2.2 Financial Overview 7.2.3 Product Portfolio 7.2.4 Business Strategies 7.2.5 Recent Developments 7.3 GlaxoSmithKline plc 7.3.1 Company Overview 7 Transparency Market Research

  8. Heparin Market 7.3.2 Financial Overview 7.3.3 Product Portfolio 7.3.4 Business Strategies 7.3.5 Recent Developments 7.4 Leo Pharma A/S 7.4.1 Company Overview 7.4.2 Financial Overview 7.4.3 Product Portfolio 7.4.4 Business Strategies 7.4.5 Recent Developments 7.5 Pfizer, Inc. 7.5.1 Company Overview 7.5.2 Financial Overview 7.5.3 Product Portfolio 7.5.4 Business Strategies 7.5.5 Recent Developments 7.6 Sanofi S.A. 7.6.1 Company Overview 7.6.2 Financial Overview 7.6.3 Product Portfolio 7.6.4 Business Strategies 7.6.5 Recent Developments 7.7 Syntex S.A. 7.7.1 Company Overview 8 Transparency Market Research

  9. Heparin Market 7.7.2 Financial Overview 7.7.3 Product Portfolio 7.7.4 Business Strategies 7.7.5 Recent Developments List of Figures FIG. 1 Europe Heparin Market Segmentation FIG. 2 Europe Heparin Market, by Geography, 2013 (USD Million) FIG. 3 Value Chain Analysis: Europe Heparin Market FIG. 4 Market Attractiveness Analysis of the Europe Heparin Market, by Country FIG. 5 Market Share Analysis: Europe Heparin Market, by Key Players, 2013 (Value %) FIG. 6 Europe Unfractionated Heparin Market Revenue, 2012 – 2022 (USD Million) FIG. 7 Europe Low Molecular Weight Heparin Market Revenue, 2012 – 2022 (USD Million) FIG. 8 Europe Ultra-low Molecular Weight Heparin Market Revenue, 2012 – 2022 (USD Million) FIG. 9 United Kingdom Heparin Market Revenue, by Product, 2012 – 2022 (USD Million) FIG. 10 Germany Heparin Market Revenue, by Product, 2012 – 2022 (USD Million) FIG. 11 France Heparin Market Revenue, by Product, 2012 – 2022 (USD Million) FIG. 12 Spain Heparin Market Revenue, by Product, 2012 – 2022 (USD Million) FIG. 13 Italy Heparin Market Revenue, by Product, 2012 – 2022 (USD Million) FIG. 14 Italy Heparin Market Revenue, by Product, 2012 – 2022 (USD Million) FIG. 15 Dr. Reddy's Laboratories Ltd.: Annual Revenue, 2011 – 2013 (USD Million) FIG. 16 Fresenius Kabi: Annual Revenue, 2011 – 2013 (USD Million) FIG. 17 GlaxoSmithKline plc: Annual Revenue, 2011 – 2013 (USD Million) FIG. 18 LEO Pharma A/S: Annual Revenue, 2011 – 2013 (USD Million) 9 Transparency Market Research

  10. Heparin Market FIG. 19 Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million) FIG. 20 Sanofi S.A. : Annual Revenue, 2011 – 2013 (USD Million) List of Tables TABLE 1 Market Snapshot: Europe Heparin Market TABLE 2 Europe Heparin Market, Average Prices, 2015 and 2022 (USD) TABLE 3 Europe Heparin Market Revenue, by Product, 2012 – 2022 (USD Million) TABLE 4 Europe Heparin Market Revenue, by Country, 2012 – 2022 (USD Million) About Us Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward- looking insight for thousands of decision makers. We are privileged with a highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Contact Mr.Nachiket 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 10 Transparency Market Research

  11. Heparin Market USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ 11 Transparency Market Research